PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF SERIES B CONVERTIBLE PREFERRED STOCK OFFERING
PetVivo Holdings (OTCQB: PETV) has secured a $5 million equity financing through a Series B Convertible Preferred Stock offering. The company received an initial $600,000 on March 26, 2025, with the remaining $4.4 million expected within 60 days.
The funds will support the commercialization of two key products: SPRYNG® with OsteoCushion® Technology, an intra-articular injectable veterinary device using sterilized extra-cellular matrix microparticles for joint pain management, and Precise PRP®, an off-the-shelf platelet-rich plasma product for veterinary use.
Precise PRP® is notable for being leucoreduced and containing 4 billion platelets per vial at 500,000 platelets per microliter concentration, requiring no blood draw or centrifugation for administration in dogs and horses.
PetVivo Holdings (OTCQB: PETV) ha ottenuto un finanziamento azionario di 5 milioni di dollari attraverso un'offerta di azioni privilegiate convertibili di Serie B. L'azienda ha ricevuto un primo importo di 600.000 dollari il 26 marzo 2025, con i restanti 4,4 milioni attesi entro 60 giorni.
I fondi sosterranno la commercializzazione di due prodotti chiave: SPRYNG® con Tecnologia OsteoCushion®, un dispositivo veterinario iniettabile intra-articolare che utilizza microparticelle di matrice extracellulare sterilizzata per la gestione del dolore articolare, e Precise PRP®, un prodotto di plasma ricco di piastrine pronto all'uso per uso veterinario.
Precise PRP® è notevole per essere leucoredotto e contenere 4 miliardi di piastrine per flacone con una concentrazione di 500.000 piastrine per microlitro, non richiedendo prelievo di sangue o centrifugazione per la somministrazione in cani e cavalli.
PetVivo Holdings (OTCQB: PETV) ha asegurado un financiamiento de capital de 5 millones de dólares a través de una oferta de acciones preferentes convertibles de Serie B. La compañía recibió un monto inicial de 600,000 dólares el 26 de marzo de 2025, y se espera que los restantes 4.4 millones lleguen en un plazo de 60 días.
Los fondos apoyarán la comercialización de dos productos clave: SPRYNG® con Tecnología OsteoCushion®, un dispositivo veterinario inyectable intraarticular que utiliza micropartículas de matriz extracelular esterilizada para el manejo del dolor articular, y Precise PRP®, un producto de plasma rico en plaquetas listo para usar en veterinaria.
Precise PRP® es notable por ser leucorreducido y contener 4 mil millones de plaquetas por vial a una concentración de 500,000 plaquetas por microlitro, sin necesidad de extracción de sangre ni centrifugación para su administración en perros y caballos.
PetVivo Holdings (OTCQB: PETV)는 500만 달러의 자본금을 시리즈 B 전환 우선주 발행을 통해 확보했습니다. 이 회사는 2025년 3월 26일에 초기 60만 달러를 받았으며, 나머지 440만 달러는 60일 이내에 받을 것으로 예상하고 있습니다.
이 자금은 두 가지 주요 제품의 상용화를 지원합니다: SPRYNG®와 OsteoCushion® 기술, 관절 통증 관리를 위한 멸균된 세포외 기질 미세입자를 사용하는 관절 내 주사형 수의학 장치, 그리고 Precise PRP®, 수의학 용으로 준비된 혈소판 농축 혈장 제품입니다.
Precise PRP®는 백혈구가 감소되어 있으며, 1바이알당 40억 개의 혈소판을 포함하고 있으며, 미세리터당 50만 개의 혈소판 농도로, 개와 말에게 투여하기 위해 혈액 채취나 원심분리가 필요하지 않습니다.
PetVivo Holdings (OTCQB: PETV) a sécurisé un financement en capital de 5 millions de dollars grâce à une offre d'actions privilégiées convertibles de Série B. L'entreprise a reçu un montant initial de 600 000 dollars le 26 mars 2025, les 4,4 millions restants étant attendus dans les 60 jours.
Les fonds soutiendront la commercialisation de deux produits clés : SPRYNG® avec Technologie OsteoCushion®, un dispositif vétérinaire injectable intra-articulaire utilisant des microparticules de matrice extracellulaire stérilisées pour la gestion de la douleur articulaire, et Precise PRP®, un produit de plasma riche en plaquettes prêt à l'emploi pour un usage vétérinaire.
Precise PRP® se distingue par le fait qu'il est leucoréduit et contient 4 milliards de plaquettes par flacon à une concentration de 500 000 plaquettes par microlitre, ne nécessitant ni prélèvement sanguin ni centrifugation pour l'administration chez les chiens et les chevaux.
PetVivo Holdings (OTCQB: PETV) hat eine Eigenkapitalfinanzierung in Höhe von 5 Millionen Dollar durch ein Angebot von umwandelbaren Vorzugsaktien der Serie B gesichert. Das Unternehmen erhielt am 26. März 2025 eine erste Zahlung von 600.000 Dollar, während die verbleibenden 4,4 Millionen innerhalb von 60 Tagen erwartet werden.
Die Mittel werden die Kommerzialisierung von zwei Schlüsselprodukten unterstützen: SPRYNG® mit OsteoCushion®-Technologie, einem intraartikulären injizierbaren veterinärmedizinischen Gerät, das sterilisierten extrazellulären Matrixmikropartikel zur Behandlung von Gelenkschmerzen verwendet, und Precise PRP®, einem gebrauchsfertigen plättchenreichen Plasma-Produkt für den veterinärmedizinischen Einsatz.
Precise PRP® zeichnet sich dadurch aus, dass es leukoreduziert ist und 4 Milliarden Blutplättchen pro Flasche bei einer Konzentration von 500.000 Plättchen pro Mikroliter enthält, ohne dass eine Blutentnahme oder Zentrifugation für die Anwendung bei Hunden und Pferden erforderlich ist.
- Secured $5 million in equity financing
- Initial $600,000 already received with remaining $4.4M expected within 60 days
- Strengthened balance sheet for product commercialization
- Precise PRP offers unique off-the-shelf solution with consistent dosing
- Dilutive financing through convertible preferred stock offering
- Dependent on investor exercising option for remaining $4.4M investment
MINNEAPOLIS, March 31, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the “Company”) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for horses, dogs and other companion animals announced today that the Company has recently entered into a Subscription Agreement to receive Five Million Dollars (
The proceeds from this Offering are earmarked to assist the Company in the commercialization of its signature products, SPRYNG® with OsteoCushion® Technology and Precise PRP®. Spryng is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
PrecisePRP is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter.
John Lai, Chief Executive Officer of PetVivo Holdings, Inc., commented “The completion of our Series B Offering significantly strengthens our balance sheet and allows us to accelerate the advancement of our flagship products, Spryng with OsteoCushion Technology and PrecisePRP. The strong support from this key investor underscores the high level of confidence in our Company’s potential. With the investment of
”For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit https://petvivo.com/ and https://www.sprynghealth.com.
No Offer or Solicitation
Nothing contained herein shall constitute an offer to sell or the solicitation of an offer to buy any security. The shares of Series B Convertible Preferred Stock (“Shares”) were offered and sold to persons reasonably believed to be qualified accredited investors pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Shares have not been and will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
How much funding did PetVivo (PETV) secure in their Series B offering?
What are the key features of PetVivo's Precise PRP product?
How does PetVivo's SPRYNG technology work for joint pain management?
What will PetVivo use the Series B funding for?
